With over 20 years of product development experience, XOMA and its Project and Alliance Management Team are committed to providing highly effective leadership and management expertise to cross-functional project teams.  Each program and relationship is unique, but all require ongoing communication, seamless functional transitions and the flexibility to meet overall program objectives. And to maximize information sharing, ensure document control and enhance communications, XOMA also provides each partner access to project-specific secured web-accessible databases. These databases allow XOMA and its partners to review data or reports in real time from initiation of antibody discovery through clinical enrollment, regulatory filings and production quality documents.

A Proven Success in Partnered Product Development and Manufacturing

RAPTIVA® is a recombinant humanized antibody directed against CD11a, approved for the treatment of chronic, moderate-to-severe plaque psoriasis. RAPTIVA® was initially developed by Genentech, Inc. in the early 1990’s. By the mid-90’s Genentech’s development group was operating at full capacity. With its development pathway overloaded, Genentech needed a partner. In 1996, Genentech entered into a collaboration with XOMA to develop RAPTIVA®. XOMA assumed responsibility for scale-up and manufacturing for preclinical and clinical purposes, completion of toxicology and other preclinical studies, conduct of phase I and II clinical studies and manufacturing of cGMP phase III product. RAPTIVA® is sold in the U.S., European Union and other countries worldwide.